PRKDC regulates cGAMP to enhance immune response in lung cancer treatment
The findings of this study reveal that PRKDC can predict poor survival of patients with LUAD. Additionally, SB505124 enhances the efficacy of 2',3'-cGAMP-based immunotherapy in patients exhibiting a high PRKDC expression.
Authors
- Zhanghao Huang (ORCID: https://orcid.org/0000-0002-3223-8625)
- Youlang Zhou
- Ruoxuan Huang (ORCID: https://orcid.org/0000-0001-7156-4856)
- Jiahai Shi (ORCID: https://orcid.org/0000-0002-8635-5376)
- Jun Zhu (ORCID: https://orcid.org/0000-0003-0596-0230)
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-26
- DOI
- https://doi.org/10.3389/fimmu.2024.1497570
- Citations
- 4
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.96